HCmed Innovations Co (TPE:6934) EBIT: NT$-28.20 Mil (TTM As of Dec. 2025)


TPE:6934 HCmed Innovations Co Ltd TPE:6934
11 GF Score
Price NT$68.00
! 4 Warning Signs
View Full Analysis

What is HCmed Innovations Co EBIT?

HCmed Innovations Co TPE:6934 -2.16% 11 EBIT is NT$-28.20 Mil as of Dec. 2025. GuruFocus rates TPE:6934 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review.

HCmed Innovations Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$7.51 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-28.20 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. HCmed Innovations Co's annualized ROC % for the quarter that ended in Dec. 2025 was 13.51%. HCmed Innovations Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 25.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. HCmed Innovations Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1.23%.

HCmed Innovations Co  (TPE:6934) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

HCmed Innovations Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=19.476 * ( 1 - 0% )/( (115.017 + 173.39)/ 2 )
=19.476/144.2035
=13.51 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=354.657 - 22.298 - ( 235.882 - max(0, 37.119 - 254.461+235.882))
=115.017

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=441.189 - 40.013 - ( 263.545 - max(0, 59.769 - 287.555+263.545))
=173.39

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

HCmed Innovations Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=30.052/( ( (94.061 + max(-5.793, 0)) + (139.773 + max(-17.802, 0)) )/ 2 )
=30.052/( ( 94.061 + 139.773 )/ 2 )
=30.052/116.917
=25.70 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.405 + 14.547 + 3.454) - (22.298 + 0 + 1.901)
=-5.793

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.381 + 13.646 + 3.981) - (40.013 + 0 + 1.797)
=-17.802

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

HCmed Innovations Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-28.197/2294.548
=-1.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HCmed Innovations Co EBIT Related Terms

HCmed Innovations Co EBIT Historical Data

* Premium members only.

The historical data trend for HCmed Innovations Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HCmed Innovations Co EBIT Chart

HCmed Innovations Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
-40.14 -143.97 -166.10 -50.69 -127.20

HCmed Innovations Co Quarterly Data
Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.81 38.30 0.00 -35.71 7.51

TPE:6934 vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, HCmed Innovations Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HCmed Innovations Co EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, HCmed Innovations Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where HCmed Innovations Co's EV-to-EBIT falls into.


TPE:6934
11GF Score
HCmed Innovations Co Ltd TPE:6934
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HCmed Innovations Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-28.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-28.20 Mil mean?
HCmed Innovations Co (TPE:6934) has a EBIT of NT$-28.20 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on HCmed Innovations Co.
Is HCmed Innovations Co's EBIT too high?
HCmed Innovations Co's current EBIT is NT$-28.20 Mil. Overall, HCmed Innovations Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does HCmed Innovations Co's EBIT compare to ABT and SYK?
HCmed Innovations Co's EBIT of NT$-28.20 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on HCmed Innovations Co. HCmed Innovations Co's current EBIT is NT$-28.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCmed Innovations Co stock overvalued right now?
HCmed Innovations Co (TPE:6934) has a current EBIT of NT$-28.20 Mil. The current EBIT is NT$-28.20 Mil. HCmed Innovations Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For HCmed Innovations Co (TPE:6934), the current EBIT is NT$-28.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HCmed Innovations Co Business Description

Address Dunhua S. Road, Rm.B, 10th floor., No.319, Sec.2, Taipei, TWN, 106033
HCmed Innovations Co Ltd is engaged in designing, developing, manufacturing and selling drug delivery system. It is focused on inhalation therapy to create integrated drug nebulizer combination products featuring nebulization therapeutic drugs that include small molecule synthetics and large molecule biologics, as either solutions, suspensions, and even difficult-to-deliver high viscosity drugs. Its product includes Pulmogine. Geographically, the company operates in America, Europe, Asian and African regions.
11GF Score

Get the complete analysis for TPE:6934

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$68.00
Price